Armando de Oliveira Schubach Selected Research

Meglumine Antimoniate

1/2021	An old drug and different ways to treat cutaneous leishmaniasis: Intralesional and intramuscular meglumine antimoniate in a reference center, Rio de Janeiro, Brazil.
1/2021	Serine proteases profiles of Leishmania (Viannia) braziliensis clinical isolates with distinct susceptibilities to antimony.
1/2019	Good response to pentamidine isethionate in a case of Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis that was difficult to treat: Case Report.
11/2018	Favorable responses to treatment with 5 mg Sbv/kg/day meglumine antimoniate in patients with American tegumentary leishmaniasis acquired in different Brazilian regions.
12/2017	Low dose systemic or intralesional meglumine antimoniate treatment for American tegumentary leishmaniasis results in low lethality, low incidence of relapse, and low late mucosal involvement in a referral centre in Rio de Janeiro, Brazil (2001-2013).
3/2017	Intralesional treatment with meglumine antimoniate in three patients with New World cutaneous leishmaniasis and large periarticular lesions with comorbidities.
11/2016	Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis.
1/2015	In vitro sensitivity of paired Leishmania (Viannia) braziliensis samples isolated before meglumine antimoniate treatment and after treatment failure or reactivation of cutaneous leishmaniasis.
7/2014	Resolution of cutaneous leishmaniasis after acute eczema due to intralesional meglumine antimoniate.
7/2014	Factors associated to adherence to different treatment schemes with meglumine antimoniate in a clinical trial for cutaneous leishmaniasis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Armando de Oliveira Schubach Research Topics

Disease

12	Cutaneous Leishmaniasis 01/2021 - 05/2005
7	Leishmaniasis 01/2021 - 12/2004
2	Visceral Leishmaniasis (Kala Azar) 07/2008 - 12/2004
1	Sporotrichosis 01/2019
1	Communicable Diseases (Infectious Diseases) 12/2017
1	Varicose Ulcer (Ulcer, Venous) 04/2017
1	Ulcer 04/2017
1	Wounds and Injuries (Trauma) 04/2017
1	Infections 07/2014
1	Eczema 07/2014
1	Hemorrhage 07/2014
1	Pathologic Complete Response 11/2008

Drug/Important Bio-Agent (IBA)

13	Meglumine AntimoniateIBA 01/2021 - 05/2005
2	Pharmaceutical PreparationsIBA 01/2021 - 01/2019
2	Pentamidine (NebuPent)FDA LinkGeneric 01/2019 - 03/2011
2	DNA (Deoxyribonucleic Acid)IBA 04/2017 - 04/2010
2	Immunoglobulin G (IgG)IBA 01/2009 - 07/2008
1	Amphotericin B (Amphotericin)FDA LinkGeneric 01/2019
1	Melanins (Melanin)IBA 01/2019
1	Prednisone (Sone)FDA LinkGeneric 04/2017
1	AntimonyIBA 01/2017
1	Leukocyte Elastase (Neutrophil Elastase)IBA 01/2015
1	Histones (Histone)IBA 01/2015
1	SteroidsIBA 07/2014
1	Kinetoplast DNA (kDNA)IBA 04/2010
1	EnzymesIBA 01/2009
1	AntibodiesIBA 01/2009
1	Itraconazole (Sporanox)FDA LinkGeneric 11/2008
1	AntigensIBA 07/2008
1	IsoenzymesIBA 12/2004

Therapy/Procedure

4	Therapeutics 04/2017 - 08/2012
1	Complementary Therapies (Alternative Medicine) 12/2017
1	Intralesional Injections 03/2017
1	Aftercare (After-Treatment) 01/2015
1	Injections 01/2015
1	Contraindications 08/2012
1	Euthanasia (Mercy Killing) 12/2004